Robbins LLP Reminds Cytokinetics, Inc. Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against CYTK

SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Cytokinetics, Inc. (NASDAQ: CYTK) securities between December 27, 2023 and May 6, 2025. Cytokinetics is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Cytokinetics, Inc. (CYTK) Misled Investors About its New Drug Application Submission

According to the complaint, during the class period, defendants made materially false and misleading statements regarding the timeline for the New Drug Application ("NDA") submission and approval process for aficamten. Specifically, Defendants represented that the Company expected approval from the U.S. Food and Drug Administration for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company's failure to submit a Risk Evaluation and Mitigation Strategy that could delay the regulatory process. Shareholders suffered financial losses when the truth was revealed.

What Now: You may be eligible to participate in the class action against Cytokinetics, Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers with the court by November 17, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. 

To be notified if a class action against Cytokinetics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

SOURCE Robbins LLP